XBIT
XBiotech Inc.2.4500
-0.0800-3.16%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
74.69MP/E (TTM)
-Basic EPS (TTM)
-0.95Dividend Yield
0%Recent Filings
10-K
FY2025 results
XBiotech posted a $45.5M net loss for FY2025 ended December 31, 2025, up from $38.5M in 2024, driven by $47.4M R&D expenses (85% of total opex) versus $37.8M prior year; no revenue as manufacturing contracts ended. Cash burned $39.9M in operations, ending at $125.6M after repaying a $10M related-party loan. R&D surged on $21.8M executive severance/bonus and $2.7M stock comp, while clinical trials paused. No quarterly breakdowns disclosed. Steady $1.7M depreciation signals infrastructure support. Leadership churn risks pipeline momentum.
8-K
CEO retires; interim named
XBiotech's John Simard retires as President and CEO effective December 8, 2025, after notifying the board on December 5; he stays as Chairman and shifts to a paid consulting role with severance. Chief Scientific Officer Sushma Shivaswamy steps in as interim CEO, her base salary rising to $750,000. Leadership transitions smoothly. No related arrangements disclosed.
10-Q
Q3 FY2025 results
XBIOTECH INC. 10-Q filing for Q3 FY2025 ended September 30, 2025 contains no financial statements, revenue, profitability metrics, or y/y q/q deltas; numbers not disclosed. Balance sheet, income statement, cash flow, and MD&A details omitted from provided excerpt. Non-GAAP metrics not disclosed in the 10-Q. Liquidity, debt, M&A, or regulation absent. Competition remains a key risk from Risk Factors.
8-K
New CEO Simard deal signed
XBiotech inked a new employment deal with CEO John Simard, effective October 1, 2025, locking in his $1.25M base salary and $4.53M annual bonus—both inflation-adjusted—while formalizing five-year pay trends. It secures his leadership yet eases transition via three years' severance on retirement, disability, or no-cause exit, plus 18 months' consulting pay if he retires. Non-compete binds him during severance.
8-K
Annual meeting approvals secured
XBiotech's stockholders overwhelmingly approved all proposals at the August 29, 2025 annual meeting, electing John Simard, Thomas Kündig, Craig Rademaker, Tevi D. Troy, and David Soffer to the board with over 90% support each. They ratified Whitley Penn LLP as auditors for 2025, endorsed executive compensation on an advisory basis, and greenlit the 2025 Equity Incentive Plan. Strong alignment with board recommendations signals investor confidence. Yet broker non-votes topped 2.8 million shares.
IBIO
iBio, Inc.
2.06+0.23
QTTB
Q32 Bio Inc.
2.88-0.17
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
STTK
Shattuck Labs, Inc.
2.94-0.12
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05
XLO
Xilio Therapeutics, Inc.
0.65+0.00
XNCR
Xencor, Inc.
16.55-0.24
XRTX
XORTX Therapeutics Inc.
0.59-0.01
XTLB
XTL Biopharmaceuticals Ltd.
0.78-0.03
ZURA
Zura Bio Limited
4.12+0.05